开发用于肿瘤治疗的肿瘤浸润淋巴细胞治疗的创新策略。

Developing innovative strategies of tumor‑infiltrating lymphocyte therapy for tumor treatment.

机构信息

R&D, Qingdao Sino‑cell Biomedicine Co., Ltd., Qingdao, Shandong 266000, P.R. China.

Phase Ⅰ Clinical Research Center Affiliated, Linyi Tumor Hospital, Linyi, Shandong 276000, P.R. China.

出版信息

Oncol Rep. 2024 Jun;51(6). doi: 10.3892/or.2024.8744. Epub 2024 Apr 26.

Abstract

Cancer is the main cause of global mortality, and thus far, effective therapeutic strategies for cancer treatment are in high demand. Adoptive transfer of tumor‑infiltrating lymphocytes (TILs) represents a promising avenue in immunotherapy for the management of malignancies. The clinical safety and efficacy of TIL‑based therapy have been established through numerous rigorous clinical trials. However, the efficacy of TIL infusion in inducing an anti‑tumor response is limited to a subset of clinical patients with cancer. Therefore, there is an urgent need to develop innovative strategies aimed at enhancing the effectiveness of TIL‑based therapy. In the present review, the developmental history of TIL‑based therapy was systematically summarized and analyzed, while also presenting a unique perspective on enhancing the multi‑dimensional anti‑tumor capabilities of TILs. The insight and conclusions presented in this review may contribute to improving the efficacy of TIL‑based therapy and expediting its development.

摘要

癌症是全球死亡的主要原因,因此,目前非常需要有效的癌症治疗策略。过继转移肿瘤浸润淋巴细胞(TIL)是一种很有前途的免疫疗法,可用于治疗恶性肿瘤。基于 TIL 的治疗的临床安全性和疗效已通过大量严格的临床试验得到证实。然而,TIL 输注诱导抗肿瘤反应的疗效仅限于癌症的一部分临床患者。因此,迫切需要开发旨在提高 TIL 治疗效果的创新策略。在本综述中,系统地总结和分析了基于 TIL 的治疗的发展历史,同时也提出了增强 TIL 多维抗肿瘤能力的独特观点。本文综述中提出的观点和结论可能有助于提高 TIL 治疗的疗效并加速其发展。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0876/11082634/4ececdc28c5d/or-51-06-08744-g00.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索